of Experimental Dermatology, a premier journal of investigative dermatology. The results of the study suggest that six weeks of treatment with ELASTIderm can enhance the biosynthesis of elastin in skin.

Periorbital skin biopsies were obtained from female subjects, with photoaged skin, who participated in a randomized, double-blind, multi-center study evaluating the clinical effects of ELASTIderm eye treatment. Histological analyses were performed on the biopsied tissue by the Departments of Dermatology and Cutaneous Biology, and Biochemistry and Molecular Biology at Jefferson Medical College, under the direction of Dr. Jouni Uitto, a dermatologist and world-renowned expert in extracellular matrix biology and pathology.

Results from the histological analyses suggest that repair and regeneration of the elastic fiber network occurred during the 6 weeks of treatment with ELASTIderm. Regeneration of the elastic fiber network is thought to be due to reduced degradation of the elastic fibers or enhanced biosynthesis of tropoelastin, the precursor molecule of elastin.

"As skin ages it naturally loses elasticity and recoil, a process compounded by overexposure to the sun. There are few products that can reverse these changes," said Jouni Uitto, MD, PhD, Chair, Department of Dermatology and Cutaneous Biology, Jefferson Medical College in Philadelphia and investigator of the study. "The data show that ELASTIderm eye treatment can help increase the presence of elastic fibers in the treated periorbital areas of skin. This improvement is likely to be caused by the bi-metal complex in the product."

Fine lines and wrinkles are the result of sun exposure and the normal intrinsic aging process, which contribute to the loss of elastin. ELASTIderm eye treatment is a one-of-a-kind topical eye treatment clinically proven to help restore elasticity to skin around the eye and reduce the appearance of fine lines and wrinkles.

"While most products target either collagen or elastin, ELASTIderm eye treatment is unique because it helps increase production of both, reinforcing Obagi Medical Products as the leader in science-based skincare products," said Steven Carlson, Chief Executive Officer of Obagi Medical Products. "ELASTIderm eye treatment uses Obagi's exclusive Penetrating Therapeutics(TM) technology that allows for greater penetration across the skin barrier to help stimulate elasticity and collagen to enhance the resilience of the skin around the eyes."

ELASTIderm Eye treatment is a novel eye treatment that is clinically proven to help the natural abilities of skin to repair photodamage by decreasing the number of visible fine lines and wrinkles and increasing the elasticity of the skin. Although most cosmetic treatment products to date utilize moisturizing ingredients to help reduce the appearance of lines around the eyes, ELASTIderm eye treatment utilizes a patent-pending bi-mineral complex technology with malonic acid to offer a new, clinically-proven approach to anti-aging treatment without the use of line-plumping moisturizers. Visit www.ELASTIderm.com for more information.

Obagi Medical Products develops and commercializes skin health products for the dermatology, plastic surgery, and related aesthetic markets. Using its Penetrating Therapeutics(TM) technologies, Obagi Medical's products are designed to improve penetration of agents across the skin barrier for common and visible skin conditions in adult skin including chloasma, melasma, senile lentigines, acne vulgaris and sun damage. The history of Obagi's skin care product introductions is as follows: Obagi Nu-Derm(R), 1988; Obagi-C(R) Rx (the first and only prescription-strength vitamin C and hydroquinone system), 2004; Obagi(R) Professional-C (a line of highly stable vitamin C serums), 2005; Obagi(R) Condition and Enhance for use with cosmetic procedures to enhance patient outcomes and satisfaction, 2006; Obagi ELASTIderm(TM) eye treatment and Obagi CLENZIderm(R) M.D. acne therapeutic systems, 2007; a formulation of Obagi CLENZIderm(R) M.D. Systems for normal to dry skin, June 2007; and Obagi ELASTIderm(TM) Decolletage System, January 2008 and SoluCLENZ Rx Gel(TM) for the pharmacy channel in August 2008. Visit www.obagi.com for information.

This is cache, read story here